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Background: A previous study indicated that a single application of 4% dimeticone liquid gel was effective in
treating head louse infestation. This study was designed to confirm this in comparison with two applications of 1%
permethrin.
Methods: We have performed a single centre parallel group, randomised, controlled, open label, community based
trial, with domiciliary visits, in Cambridgeshire, UK. Treatments were allocated through sealed instructions derived
from a computer generated list. We enrolled 90 children and adults with confirmed head louse infestation analysed
by intention to treat (80 per-protocol after 4 drop outs and 6 non-compliant). The comparison was between 4%
dimeticone liquid gel applied once for 15 minutes and 1% permethrin creme rinse applied for 10 minutes, repeated
after 7 days as per manufacturer’s directions. Evaluated by elimination of louse infestation after completion of
treatment application regimen.
Results: Intention to treat comparison of a single dimeticone liquid gel treatment with two of permethrin gave
success for 30/43 (69.8%) of the dimeticone liquid gel group and 7/47 (14.9%) of the permethrin creme rinse group
(OR 13.19, 95% CI 4.69 to 37.07) (p < 0.001). Per protocol results were similar with 27/35 (77.1%) success for
dimeticone versus 7/45 (15.6%) for permethrin. Analyses by household gave essentially similar outcomes.
Conclusions: The study showed one 15 minute application of 4% dimeticone liquid gel was superior to two
applications of 1% permethrin creme rinse (p < 0.001). The low efficacy of permethrin suggests it should be
withdrawn.
Trial registration: Current Controlled Trials ISRCTN88144046.
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In Europe control of head louse infestation is now mainly
achieved by use of physically acting preparations [1]. The
majority of these are based on the polydimethysiloxane,
known as dimeticone. This compound exists in a variety
of forms from the volatile hexamethyldisiloxane, with a
viscosity of just 0.65 centistokes (cSt) through to high mo-
lecular weight gums with a viscosity of several million cSt.
The level of polymerisation during manufacture results in* Correspondence: ian@insectresearch.com
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reproduction in any medium, provided the ora range of materials with such variable physical characte-
ristics that selection of the right molecular weight and
viscosity is potentially critical for gaining maximum effect-
iveness in this application.
The first dimeticone based product was Hedrin 4%
lotion, approved as a medicine for sale in the UK in 2005,
which used dimeticone of 100K cSt viscosity in a
decamethylcyclopentasiloxane (cyclomethicone D5) vola-
tile fluid vehicle. This product is also widely used in
Europe, mostly as a class I medical device, and has been
shown efficacious in several clinical field studies [2-4].
Since that time variant formulations have been developedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duct and also the cosmetic characteristics.
The original 4% dimeticone lotion is applied for 8
hours or overnight on two occasions a week apart. Sub-
sequent investigations both in the laboratory and in cli-
nical trials have looked at shorter application times for
this product and for the variants. One recently described
study outcome found that no lice of any development
stage were present following the first application of
product in a two treatment regimen using a 15 minutes
exposure time for a spray gel variant [5]. This report
describes the first study investigating the efficacy of a
single application regimen for Hedrin 4% dimeticone li-
quid gel, tested in a comparison trial against two applica-
tions of 1% permethrin creme rinse.
Methods
Participants
We recruited participants mostly through contact with
families who had expressed a wish to be involved in re-
search and advertising on local radio and in parish mag-
azines. An information booklet was sent to each family
and an appointment arranged for an investigator to visit.
All household members were offered screening for head
lice using a standard detection comb (“PDC”, KSL Con-
sulting, Denmark). The intensity of infestation was graded
as heavy, medium, or light using criteria employed in pre-
vious studies [2-4].
We also used eligibility criteria from previous studies
[2-4], excluding those with known sensitivity to treat-
ment components or long terms scalp conditions other
than lice, those treated for lice within 2 weeks previ-
ously, and who had used hair bleach, dyes, or permanent
waves, or had been treated with trimethoprim containing
preparations within the last month. Pregnancy, breast
feeding, participation in another clinical study within 4
weeks or prior participation in the current study, were
also grounds for exclusion. All eligible family members
could be enrolled and on agreement were conducted
through a standard informed consent and assent proce-
dure. The practical lower age limit was 2 years although
approval for the products was as young as 6 months.
There was no upper age limit.
Demographic data were collected after consent was
taken, including gender, age, hair characteristics, and ap-
pointments made for subsequent assessment and treat-
ment visits. No payment was offered for participation.
Ineligible household members with lice were offered
standard of care treatment using 4% dimeticone liquid
gel to minimise reinfestation of study participants.
Ethics
Ethical approval was granted by Central London Research
Ethics Committee 2 (EudraCT 2011-000257-23).The study was conducted in compliance with Good
Clinical Practices, and conformity with the principles of
the Declaration of Helsinki and of European Union Dir-
ective 2001/20/EC. All participants received study infor-
mation at least 24 hours before enrolment and all stated
that they understood the purpose and requirements of the
investigation before giving consent. Parents or guardians
gave written consent for children younger than 16 years
and children also provided written assent, where able to
do so, witnessed by the parent or guardian.
Treatments
The products used for this randomised controlled trial
were different in both appearance and method of appli-
cation so blinding at the time of treatment was not
possible.
4% dimeticone liquid gel (Hedrin Once liquid gel,
Thornton & Ross Ltd, Huddersfield, UK) contains 4%
high molecular weight dimeticone, 1,6,10-dodecatrien-3-
ol,3,7,11-trimethyl, PEG/PPG dimeticone co-polymer,
and silica silylate. It was supplied in 150mL polyethylene
bottles and applied systematically to dry hair over the
whole scalp using the inbuilt dropper cap. In each case
the investigators spread the fluid through the hair using
their fingers to ensure thorough coverage. The product
was applied once for 15 minutes and then washed out
using shampoo and water.
1% permethrin creme rinse (Lyclear creme rinse,
Omega Pharma UK, London, UK) contains 1% permeth-
rin in a conditioner base with 20% isopropanol. It was
supplied in 59mL HDPE bottles with a flip cap. It was
applied liberally to shampoo washed and towel dried
hair. Investigators ensured that all parts of the hair and
scalp were thoroughly coated, which in most cases re-
quired more than one bottle. This product was applied
for 10 minutes on two occasions 7 days apart followed
by rinsing with water only.
In each case parent/guardians were advised of the time
to wash the treatments off. Use of nit combs or other
pediculicides during the course of the studies was not
permitted.
Outcome measures
The primary outcome measure was elimination of infes-
tation after completion of the treatment regimen. Fol-
lowing treatment on Day 0 we performed follow-ups on
Days 1, 6, 9, and 14 by dry detection combing using the
“PDC” comb to assess the efficacy of treatment. If any
lice were found they were fixed in the case record and
the development stage subsequently recorded.
Outcomes of treatment were classified as cure, rein-
festation following cure, or treatment failure (with a
sub-category for ovicidal failure). Because one of the
treatments in this study used one application only we
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ous studies for determining outcome criteria.
Sample size
We anticipated that there was likely to be a disparity in
efficacy between dimeticone liquid gel and permethrin
creme rinse, based on previous data. Consequently, it
was possible that, if different members of a family were
randomly allocated different treatments, those receiving
the more effective preparation could be reinfested from
those receiving the less effective product. Although the
protocol allowed for identification of reinfestation at a
low level it could not address problems resulting from
heavy reinfestation. Therefore a different randomisation
model was employed in which all members of a house-
hold received the same treatment allocation, with ran-
domisation by family rather than by individual.
An analysis of the variance of the cure rates in relation
to household sizes was made using data from previous
studies and from this we estimated that the number of
participants required using the randomise-by-family ap-
proach was higher than the number required using the
randomise-by-individual approach (assuming independ-
ence and ignoring dropout) by a factor of 1.46.
For a randomise-by-individual approach, assuming a
confidence level of 95% and a power of 95%, and conser-
vatively taking the expected cure rates to be 90% for
dimeticone liquid gel and 50% for permethrin creme
rinse, we estimated the required sample size as 29 par-
ticipants per treatment. Under the same assumptions,
the required number of participants per treatment under
the randomise-by-family approach was 42, equivalent to
an estimated 22 families per treatment.
Randomisation and blinding
The randomised treatment allocation sequence was de-
rived using a free to access online computer generated
list from http://www.randomization.com (seed 25270,
22nd June 2011). Allocation at the point of delivery was
made from instruction sheets enclosed in opaque, sealed,
sequentially numbered envelopes distributed to investi-
gators in balanced blocks of eight. Participant families
were allocated the next available numbered envelope
held by the investigator. Investigators conducting follow
up visits were separate from those involved in treatment
and thus remained blind of treatment allocation.
Statistical analysis
We conducted analyses based on both the "intention-
to-treat" (ITT) and the "per-protocol" (PP) populations.
Differences between groups in baseline characteris-
tics, safety, acceptability, and efficacy were tested
using Fisher's exact test for yes/no variables and the
Mann–Whitney U test for ranked variables. Whereanalyses showed important differences in baseline cha-
racteristics between the groups, chi-squared and rank
tests stratified for these characteristics were conducted
and 95% confidence limits presented for the difference
between groups in the primary endpoint.
Results
Participants
Ninety participants from 44 households were enrolled
between 1st July and 3rd November 2011, of whom four
participants in two households later dropped out or were
lost to follow up (Figure 1). A further six participants
completed the study but were non-compliant, either
combing out lice (five participants) or out of time on
one assessment visit (one participant). Therefore the
ITT population analysed was 90, but as a result of the
protocol violations the per-protocol population was 80
across 40 households broken down as follows: dime-
ticone liquid gel = 35 participants from 20 households;
permethrin creme rinse = 45 from 20 households.
Baseline characteristics were recorded for all partici-
pants at Day 0 of whom 73 (81.1%) were female and
ranged from 2 to 45 years in age, mean age 11.7 years.
The 44 households, varied in size from 2 to 9 occupants
(mean 4.39). Numbers of participants per household
were: 1 (17 households), 2 (16 households), 3 (6 house-
holds), 4 (3 households), 5 or 6 participants (1 house-
hold each). Of the 90 participants, the initial infestation
was classified as “light” in 52, “moderate” in 17 and
“heavy” in 21. There was no difference between treat-
ments in this characteristic.
Consistent with the large proportion of females in the
study, the proportion with hair “ears to shoulders” or
“below shoulders” was very high (89.3% in the
dimeticone group and 84.9% in the permethrin group).
There were similarly high numbers of participants with
“thick” hair (61.7% and 53.8% respectively). Both groups
had approximately 37% of participants with “wavy” or
“slightly curly” hair, which is a recently observed in-
creased trend toward “wavy” hair compared with older
studies. Only a small proportion of participants had hair
that was dry (7.4%) or oily (8.1%).
Outcomes
The Day 1 analyses included all 90 participants; Day 6
analyses related to 89 participants following a drop out,
with a subsequent drop out of 2 other participants from
the same household so that 87 participants remained on
Day 9. The Day 14 analyses included 86 participants due
to one lost to follow up, with exclusion of a further 6
participants from the PP analyses for protocol violations.
For the intention to treat outcomes by individual, we
conducted an endpoint analysis of rate of cure (or ex-
ceptionally cure followed by reinfestation as defined by
CTMK05 Flowchart, Version 1.0, 11 July 2006
Assessed for eligibility
Randomised: (N = 44 households, n = 90 participants)
Not randomised:
Reason: No lice (N = 6 households)
Allocated to receive 4% dimeticone liquid gel
(N = 22 households, n = 43 participants)
Monitor adverse experiences
Follow up check by detection combing
Day 2: if lice present – collect on CRF
Day 6: if lice present – collect on CRF
Day 9: if lice present – collect on CRF
Day 14: if lice present – collect on CRF
Allocated to receive 1% permethrin creme rinse
(N = 22 households, n = 47 participants)
Monitor adverse experiences
Follow up check by detection combing
Day 2: if lice present – collect on CRF
Day 6: if lice present – collect on CRF
Monitor adverse experiences
Follow up check by detection combing
Day 9: if lice present – collect on CRF
Day 14: if lice present – collect on CRF
Apply treatment Apply treatment
Apply treatment
Analysed:
Intention to treat (N = 22 households, n = 43 participants)
Per-protocol (N = 20 households, 35 participants
Analysed:
Intention to treat (N = 22 households, n = 47 participants)
Per-protocol (N = 20 households, n = 45 participants
Non-compliant (n = 1 participant)
Lost to follow up (n = 1 participant)
Non-compliant (n = 5 participants)
Drop out (n = 3 participants)
Figure 1 Flowchart of participant progress through the study.
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According to these criteria, success was achieved overall
by 30/43 (69.8%) for dimeticone liquid gel group (26
cure, 4 reinfestation) and by 7/47 (14.9%) for the per-
methrin creme rinse group (6 cure, 1 reinfestation). The
difference in rate of success between the dimeticone and
permethrin groups was estimated as 54.9% (95% CI of
35% to 75%) (OR 13.19, 95% CI 4.69 to 37.07) which
meant that there was a highly significant (p < 0.001)
superiority of dimeticone liquid gel compared with
permethrin creme rinse in the population tested.
Dimeticone liquid gel not only showed a high ovicidal
effect, as judged by not finding young nymphs following
the single application of the product (32 participants),but also a high proportion were entirely louse free
throughout (the “cure” group of 26 participants)
(Table 1). In contrast, nearly all participants in the per-
methrin group were found to have newly hatched
nymphs at some point in the study, showing the product
has a low capacity to inhibit eggs from hatching in
addition to any impact on efficacy resulting from insecti-
cide resistance (Table 2).
We obtained per-protocol outcomes by individual by
elimination of protocol violators from the analysis to
give PP success rates of 27/35 (77.1%) for the dimeticone
liquid gel group (25 cure, 2 reinfestation) and 7/45
(15.6%) for the permethrin creme rinse group (6 cure, 1
reinfestation), giving an advantage of 61.6% (95% CI,
Table 1 Comparison of outcomes by participant – 4% dimeticone versus 1% permethrin
Outcome measurement 4% Dimeticone 1% Permethrin P value
ITT analysis
Number of households 22 22
Number of participants 43 47
Cure or cure followed by reinfestation 30 69.8% 7 14.9% < 0.001
Relative success rate (95% CI) 4.68 (2.30 – 9.35)
Cure 26 60.5% 6 12.8% < 0.001
Inhibition of egg hatching 32 74.4% 6 12.8% < 0.001
PP analysis
Number of households 20 20
Number of participants 35 45
Cure or cure followed by reinfestation 27 77.1% 7 15.6% < 0.001
Relative success rate (95% CI) 4.96 (2.45 – 10.03)
Cure 26 71.4% 6 13.3% < 0.001
Inhibition of egg hatching 30 85.7% 6 10.6% < 0.001
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dimeticone treatment over permethrin, which was also
highly significant (p < 0.001).
Using the same approach in the analysis of outcome
by household, the advantage to dimeticone liquid gelTable 2 Numbers of lice recovered – 4% dimeticone
versus 1% permethrin
Endpoint Lice collected
Day 1 Day 6 Day 9 Day 14
4% Dimeticone liquid gel
Number of participants combed 43 42 40 40
Number of participants with lice 3 4 8 12
Total lice removed 3 27 24 45
Stage 1 nymphs removed 1 5 5 2
Stage 2 nymphs removed 2 18 8 10
Stage 3 nymphs removed 0 2 7 7
Adult males removed 0 0 2 9
Adult females removed 0 2 2 17
Participants louse free (%) ITT 93.0% 90.5% 80.0% 70.0%
Participants louse free (%) PP 97.1% 94.3% 82.9% 77.1%
1% Permethrin creme rinse
Number of participants combed 47 47 47 46
Number of participants with lice 29 37 30 38
Total lice removed 359 741 259 375
Stage 1 nymphs removed 222 405 63 40
Stage 2 nymphs removed 18 204 46 51
Stage 3 nymphs removed 24 67 81 54
Adult males removed 23 17 27 91
Adult females removed 72 48 42 139
Participants louse free (%) ITT 38.3% 21.3% 36.2% 17.4%
Participants louse free (%) PP 37.8% 20.0% 37.8% 17.7%was similar (p < 0.01 or p < 0.001) for all the outcomes,
equivalent to a relative total success rate of 6.50 (95%
confidence interval (CI) 1.66 to 25.5), or an odds ratio
(OR) of 14.4 (95% CI 2.68 to 77.8), reflecting the diffe-
rence of risk for a whole household compared with that
for an individual.
All participants received the required number of treat-
ments. Dimeticone liquid gel was given once, and the
mean total product used was 63.91g (equivalent approxi-
mate cost = €6.20-€7.40). Permethrin creme rinse was
given twice, and each treatment often involved two bot-
tles and occasionally three. Over the two treatments
combined, the mean number of bottles of creme rinse
used per family member was 3.31, and the mean total
product used, 141.58g (equivalent approximate cost =
€8.30-€16.60), which was significantly (p < 0.001) more
than for dimeticone.
Adverse events
Members of seven families experienced one or more ad-
verse events, nine people treated with permethrin and
eight with dimeticone. Only two people had an adverse
event that was considered possibly related to treatment.
One was a rash on the back of the neck following each
treatment with permethrin creme rinse and the other,
dry skin, following dimeticone liquid gel. There were no
serious adverse events.
Discussion
It has long been considered that longer application times
when using head louse treatment lotions are more ef-
fective than shorter applications. This was demonstrated
in vitro using insecticide based products in which the
formulation vehicle evaporates and concentrates the ac-
tive material on the louse surface. The same approach
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such as 4% dimeticone lotion and preliminary results
from a first small study did indicate that an 8 hour or
overnight treatment was more effective than one of only
20 minutes [2]. However, in a later study we found that,
contrary to expectation, reducing the application time
for 4% dimeticone spray gel to 15 minutes not only in-
creased the effectiveness but appeared to be wholly ef-
fective with a single application [5].
Although the majority action of 4% dimeticone lotion
is derived from the dimeticone being deposited in the in-
sect spiracular and tracheal systems, resulting in
blocking of water excretion [6], it is necessary for it to
be carried there by the solvent component of the prod-
uct. If the solvent does not deliver sufficient dimeticone
to the target site the activity may be reduced.
The perceived advantage of the 4% dimeticone gel over
the original 4% lotion is that the gel seems to adhere to
the lice more effectively and, in the spray form, is easier
to direct and control ensuring all lice are killed and
those eggs close to hatching are inhibited from doing so,
as was demonstrated in our earlier study in which the
product gave 100% efficacy after the first application in
that two application trial [5]. In this study, most lice
found by investigators during follow up assessments
could be attributed to eggs that hatched after treatment,
presumably because they had been missed as a result of
inadequate spreading of the liquid gel using the dropper
bottle. Some of the children had also been observed to
present with hair dampened by sweat at the time of the
treatment application, which may have acted as a barrier
to the silicones forming a complete coating on some
louse eggs, with the possible result that silicone was not
able to reach the vulnerable surfaces of the eggs due to
the presence of a water film. The four infestations in the
ITT group without nymphs were all attributable to
reinfestation from contacts either within the family or
the local community.
This randomised controlled trial has clearly demon-
strated a difference in overall activity between a physi-
cally acting preparation using a single application and
two applications of an insecticide based product affected
by insecticide resistance. Hitherto, the majority of claims
that different products containing silicones, and other
physically acting preparations, are effective with a single
application have not been based on published clinical
data but have been extrapolations either from in vitro
data or else obtained in studies where the products were
applied twice. This study has not only confirmed efficacy
for a single application of Hedrin 4% dimeticone liquid
gel, and demonstrated a difference in overall activity be-
tween a physically acting preparation and an insecticide
based product affected by insecticide resistance, but has
also demonstrated that extrapolations about treatmentoutcomes may be misleading, in the absence of clinical
confirmation.
This trial has also provided the first clear evidence that
louse eggs do not all hatch within 7 days (Table 2). We
and many other investigators in the past had assumed
this hatching period primarily because previously we had
no other experimental evidence upon which to base a
conclusion. We found from our earlier double applica-
tion study [5] that this does not necessarily constitute a
significant problem for treatment because any lice hatch-
ing from eggs after a first treatment appear to be killed
by a second treatment at 7 days. A treatment given at
that time delivers more of the active material to any un-
hatched eggs, which further inhibits their chances of
hatching. However, this information that eggs can take
longer than one week to hatch emphasises the need for
vigilance in confirming whether a treatment has been ef-
fective, by detection combing after completion of the
treatment regimen, and also confirms the need for ad-
equate application technique [7]. So, just because more
than 90% of people appear louse free 2 days after a sec-
ond treatment it does not mean that further checks are
not necessary as some viable eggs may remain.
Although numerous lice were eliminated using the 1%
permethrin creme rinse at each of the treatment applica-
tions, more than 60% of participants received no respite
from infestation and, of those who appeared louse free
one or two days after treatment, fewer than half were
cured of their infestation, even though we used more
than twice the supposedly adequate application dose on
each participant. Why then did we choose 1% permeth-
rin as the comparator product rather than some alterna-
tive preparation? The reason 1% permethrin was used in
this study was to provide data in comparison with a
known medicinal product for those territories where
such data are required by decision makers before issuing
approvals. On this basis the number of possible compar-
ators is extremely limited because most products have a
limited geographic distribution. The only other insecti-
cide active used widely is 0.5% malathion but this was
not selected because the range of formulations used in
different territories are not comparable even within
themselves (shampoos, alcohol based lotions with or
without terpenoids added, and water based emulsions).
Additionally, the one product still listed in the UK was
not available at the time the study was conducted.
The outcome using permethrin mirrors closely the
findings of a previous investigation comparing treat-
ments using this product with and without combing [8],
and also reflects the outcome found in other studies.
Given the number of investigations in which permethrin
and other insecticide products have delivered an un-
acceptably low efficacy [3,8-12], a review of the licensing of
these preparations appears long overdue. It is understandable
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as comparators in clinical studies because they have a long
history of use and are familiar to the decision makers
within the various health services where the profile of new
products needs to be raised. However, we have found that
ethics review boards are increasingly reluctant to authorise
their use in clinical investigations primarily because their
efficacy is not much greater than using a placebo. There-
fore, as long as these products retain a marketing author-
isation, and the validity of this is not reviewed by the
various competent authorities, consumers and prescribers
will continue to use ineffective products. Consequently,
now is probably the time for such a review to take place
and for insecticide products to be removed from the mar-
ket simply because so many treatments fail.Conclusions
This study has shown that a single application of 4%
dimeticone liquid gel is effective to eliminate head louse
infestation and that the higher viscosity of this product
allows this to be achieved using a treatment time of 15
minutes. However, as with all treatments, it is possible
to miss some louse eggs during treatment, requiring
post treatment vigilance for emerging nymphs more
than 7 days after treatment.
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